Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

relate these promising in vitro data."

Steven Porter, CEO of Ceragenix stated: "The publication of peer-reviewed research on our Ceragenin(TM) compounds is an important milestone for our Company and a key element in obtaining recognition for our technology in the scientific community. We look forward to future publications from our ongoing preclinical research activities on the safety and efficacy work that is now being conducted in vivo."

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram(TM) and NeoCeram(TM). For additional information on Ceragenix, please visit www.ceragenix.com.

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of the company to raise sufficient capital to finance its planned activities; the ability of the company to satisfy its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration; suc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:8/20/2014)... -- Children aren,t the only segment of our ... disease. The Centers for Disease Control and Prevention ... many adults are not following this advice. ... and the American Lung Association in partnership with ... disease, to talk with their health care provider ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
Breaking Medicine Technology:American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
(Date:8/20/2014)... examined patient and tumor characteristics for melanomas with ... growth) in an effort to increase earlier detection ... , Author: Sarah Shen, M.B.B.S., B.Med.Sci., of ... Background: The tumor characteristic known as mitotic ... with prognosis and survival in melanoma patients. However, ...
(Date:8/20/2014)... 2014 Hundreds of Mirena IUD lawsuits ... who were allegedly injured due to spontaneous migration of ... Bergen County Superior Court, Bernstein Liebhard LLP reports. According ... 2014, the Court has established procedures regarding the production ... are part of the proceeding’s initial disposition pool. (In ...
(Date:8/20/2014)... Steven Reinberg HealthDay ... The speed at which cancer cells grow may help doctors ... Using this measure, investigators have found that the deadliest ... of older men with a long history of sun exposure. ... the researchers discovered. Rapid cell growth -- called ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... MANHATTAN, Kan., Sept. 4 The path to poor hand sanitation ... and North Carolina State Universities. , , As ... fall, the researchers said students, actions will speak louder than words. ... their hands," said Douglas Powell, an associate professor of food safety ...
... , LOS ANGELES, Sept. 4 With an estimated ... is a TOP PRIORITY for the County,s working families and a key issue ... what is the eve of Congress, return to DC to debate healthcare reform, ... more about the importance of healthcare reform and to take action to be ...
... , , BATESVILLE, Ind., Sept. 4 ... fiscal 2009 fourth quarter dividend of $0.1025 per share. This dividend ... is payable on September 30, 2009 to shareholders of record as of ... HOLDINGS, INC. , Hill-Rom is a leading worldwide manufacturer and ...
... , MADISON, N.J., Sept. 4 Quest Diagnostics Incorporated ... information and services, today announced that it was again selected to be ... (DJSI World and DJSI North America). The company is in its sixth ... the North American Index (since 2005). , , According ...
... strategies , FRIDAY, Sept. 4 (HealthDay News) -- ... United Kingdom and Australia rethink their efforts to combat ... healthy diets and exercise -- aren,t working. , In ... , Australian researchers followed more than 250 overweight and ...
... WASHINGTON, Sept. 4 Nurses appear to be taking far better care ... survey released today by the Center for American Nurses and the Women,s ... Nurse Investor Education Survey reveals that nurses may be saving for retirement, ... most nurses say they do not know what those needs will be. ...
Cached Medicine News:Health News:Getting College Students To Wash Hands, Halt Disease, Requires Giving Them Proper Tools and Spreading The Word In Ways That Get Attention, Say K-State Expert and Colleague 2Health News:Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D.C.! 2Health News:Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 2Health News:Nurses and Retirement Security: A Looming Crisis? 2Health News:Nurses and Retirement Security: A Looming Crisis? 3
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Stryker Endoscopy has combined a standardized pressurizing system with an advanced hand piece design that is lightweight and compact in order to streamline laparoscopic procedures....
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... to disintegrate renal and ureteral ... technology in a compact design ... and affordable lithotripsy system. The ... of clinical results for both ...
Medicine Products: